H-Tyr-Pro-OH | 51871-47-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Tyr-Pro-OH
• 英文别名: Tyr-Pro；tyrosyl-proline；(2S)-1-[(2S)-2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylate
• CAS: 51871-47-7
• 化学式: C₁₄H₁₈N₂O₄
• 分子量: 278.308
• InChiKey: VNYDHJARLHNEGA-RYUDHWBXSA-N

物化性质

• 沸点：
  576.0±50.0 °C(Predicted)
• 密度：
  1.371±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  H-Tyr-Pro-OH 在 N-羟基丁二酰亚胺 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: Design, synthesis, and pharmacological characterization

  摘要：

  We synthesized four new analogs of endomorphin-1 by systematic chemical modifications. To identify the best possible drug candidates for clinical pain management and to investigate the potential contribution of these alterations to the biological activity, their pharmacological properties were determined. All of the analogs showed significantly enhanced metabolic stability. The fact that centrally mediated analgesia following peripheral administration was observed with one of the analogs suggested the approach design undertaken here had validity in the development of endomorphin-1 as a successful opioid drug for the clinic. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.007
• 作为产物：
  描述：

  4-硝基苯基O-苄基-N-[(苄氧基)羰基]-L-酪氨酸酯 在 palladium on activated charcoal sodium hydroxide 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 H-Tyr-Pro-OH
  参考文献：
  名称：

  Synthesis and anti-inflammatory activity of acetylsalicylamino acids and peptides

  摘要：

  合成了若干种含水溶性乙酰水杨酰的氨基酸及中性和酸性氨基酸的肽，并对其抗炎活性进行了研究。

  DOI：

  10.1007/s10600-006-0079-5

文献信息

• Catalytic Properties of X-Prolyl Dipeptidyl Aminopeptidase from<i>Lactococcus lactis</i>subsp.<i>cremoris</i>nTR
  作者：Tsong-Rong Yan、Shih-Ching Ho、Chia-Lung Hou

  DOI：10.1271/bbb.56.704

  日期：1992.1

  An X-prolyl dipeptidyl aminopeptidase (X-PDAP; EC 3.4.14.5) was identified to be loosely bound on the inner cell membrane fraction of Lactococcus lactis subsp. cremoris nTR. The biosynthesis of X-PDAP was continuously increased before the late-log growth phase of the bacteria. Both Gly-Pro-pNA and Ala-Ala-pNA were hydrolyzed by X-PDAP; the kcat/Km value of the former was about 10-fold that of the latter. The Ki of X-Pro and Pro-X were more specific to X-PDAP than those of X-Ala. The enzyme splitting a dipeptide sequentially from β-casomorphin as a model catalytic pattern was identified and some properties of the enzyme were further characterized.

  在Lactococcus lactis subsp. cremoris nTR的内细胞膜组分上，鉴定出一种松散结合的X-脯氨酰二肽二肽基氨肽酶（X-PDAP；EC 3.4.14.5）。在细菌的后期对数生长阶段之前，X-PDAP的生物合成不断增加。X-PDAP可以水解Gly-Pro-pNA和Ala-Ala-pNA，前者的kcat/Km值约为后者的10倍。X-Pro和Pro-X的Ki比X-Ala更特异于X-PDAP。鉴定出一种以β-酪啡肽为模型的催化模式连续切割二肽的酶，并进一步表征了该酶的一些性质。
• Studies on .ALPHA.2-plasmin inhibitor fragment T-11. I. Synthesis of the protected hexadecapeptide ester corresponding to positions 11 through 26 of .ALPHA.2-plasmin inhibitor fragment T-11.
  作者：TAKASHI SASAKI、SUMIRO ISODA

  DOI：10.1248/cpb.35.2797

  日期：——

  The protected hexadecapeptide ester corresponding to positions 11 through 26 of human α2-plasmin inhibitor fragment T-11, which consists of 26 amino acids and binds to the plasmin (ogen) lysine-binding site (s), was synthesized by assembling five peptide fragments by the azide method or the dicyclohexylcarbodiimide-N-hydroxybenzotriazole method.

  通过对五个肽片段采用叠氮法或二环己基碳二亚胺-N-羟基苯并三唑法进行组装，合成了与人类α2-纤溶酶抑制剂片段T-11的第11至26位对应的受保护十六肽酯，该片段由26个氨基酸组成，并与纤溶酶（原）赖氨酸结合位点（s）结合。
• New beta-amino-alpha-hydroxycarboxylic acids and their use
  申请人：Sankyo Company Limited

  公开号：EP0498680A1

  公开（公告）日：1992-08-12

  The compounds of the invention are β-amino-α-hydroxycarboxylic acid derivatives having the formula (I): wherein: R¹ represents a group of formula R(Z)xA-    wherein R is hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heterocyclic group or R is a group of formula -NRaRb wherein Ra and Rb are hydrogen atoms, alkyl groups, unsubstituted or substituted cycloalkyl, heterocyclic, aralkenyl or aryl groups,    Z represents oxygen or sulphur;    A represents a group of formula -CO-, -COCO-, -SO-, -SO₂- or -CS-; and    x is the cipher 0 or the integer 1; R² represents a hydrogen atom, or a substituted or unsubstituted alkyl group; R³ is hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heterocyclic group; R⁴ is a hydrogen atom, a substituted or unsubstituted alkyl, aryl or heterocyclic group;    and R⁵ represents a group of formula -B-(CO)-Y-Rcy , wherein    B represents a heterocyclic group unsubstituted or substituted with at least one alkyl group;    Y represents an oxygen atom, a nitrogen atom or a sulphur atom;    y is the integer 1 when Y represents an oxygen atom or a sulphur atom, and 2 when Y represents a nitrogen atom; and    Rc represents       is hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or heterocyclic group;    and, where there are two groups or atoms represented by Rc, they are the same or different; and and pharmaceutically acceptable salts and esters thereof.

  本发明的化合物是β-氨基-α-羟基羧酸衍生物，具有以下式子（I）：其中：R¹表示以下式子的基团R（Z）xA-，其中R为氢，或取代或未取代的烷基，烯基，炔基，芳基或杂环基，或R为以下式子的基团-NRaRb，其中Ra和Rb为氢原子，烷基，未取代或取代的环烷基，杂环基，芳烯基或芳基；Z表示氧或硫；A表示以下式子的基团-CO-，-COCO-，-SO-，-SO₂-或-CS-；x为0或整数1；R²表示氢原子，或取代或未取代的烷基；R³为氢，或取代或未取代的烷基，烯基，炔基，芳基或杂环基；R⁴为氢原子，取代或未取代的烷基，芳基或杂环基；和R⁵表示以下式子的基团-B-（CO）-Y-Rcy，其中B表示未取代或取代的至少有一个烷基的杂环基；Y表示氧原子，氮原子或硫原子；当Y表示氧原子或硫原子时，y为整数1，当Y表示氮原子时，y为整数2；并且Rc表示氢原子，或取代或未取代的烷基，烯基，炔基，芳基或杂环基；当有两个由Rc表示的基团或原子时，它们是相同的或不同的；以及其药学上可接受的盐和酯。
• Nutrient compositions containing peptides
  申请人：CLINTEC NUTRITION COMPANY

  公开号：EP0457314A1

  公开（公告）日：1991-11-21

  Nutrient compositions comprise an aqueous solution of at least one dipeptide with an N-terminal amino acid selected from glutamine, aspargine, tyrosine, tryptophan, and aspargine. The C-terminal amino acid is alanine, glycine, tryptophan, arginine, proline or serine. The nutritional compositions contain from about 0.1 to 25.0 percent by weight of oligopeptides, preferably about 0.5 to 5.0 percent by weight.

  营养组合物包含至少一种二肽的水溶液，其 N 端氨基酸选自谷氨酰胺、天门冬氨酸、酪氨酸、色氨酸和天门冬氨酸。 C 端氨基酸为丙氨酸、甘氨酸、色氨酸、精氨酸、脯氨酸或丝氨酸。营养组合物含有约 0.1%至 25.0%（按重量计）的低聚肽，最好是约 0.5%至 5.0%（按重量计）。
• 新規なワカメペプチド、Ｌ−チロシル−Ｌ−プロリン及び血圧降下剤
  申请人：末綱 邦男

  公开号：JP2007182415A

  公开（公告）日：2007-07-19

  【目的】ワカメのプロテアーゼＳアマノ並びにプロレザーＦＧ−１分解液から、アンジオテンシン変換酵素阻害作用を有し、血圧降下作用を有する新規なワカメペプチド、Ｌ−チロシル−Ｌ−プロリンを提供する。【構成】ワカメをプロテアーゼ等で分解処理し、新規なアンジオテンシン変換酵素阻害作用を有するジペプチドはＬ−チロシル−Ｌ−プロリンであり、この新規なワカメペプチドは生体内での血圧降下作用を有し、毒性も極めて低い。【選択図】なし

  目的：从裙带菜蛋白酶 S-amano 和原蛋白酶 FG-1 降解液中提供一种具有血管紧张素转换酶抑制活性和降血压作用的新裙带菜肽--L-酪氨酰-L-脯氨酸。L-酪氨酰-L-脯氨酸。裙带菜海藻经蛋白酶等分解和处理后，具有新型血管紧张素转换酶抑制作用的二肽是 L-酪氨酰-L-脯氨酸，这种新型裙带菜肽在体内具有降血压作用。且毒性极低。无。